Actionable news
All posts from Actionable news
Actionable news in PRGO: PERRIGO COMPANY PLC,

Prospectuses and communications, business combinations


Pursuant to Rule 425 under the Securities Act of 1933

Subject Company:

Perrigo Company plc

Commission File No. 001-36353


October 13 th Webcast to Highlight Clear Value Creation Available to Perrigo Shareholders Through Mylans Offer

HERTFORDSHIRE, England and PITTSBURGH, October 8, 2015Mylan N.V. (Nasdaq: MYL), a leading global pharmaceutical company, will host a conference call and webcast on Tuesday, Oct. 13 th at 5:00 pm ET to review the value to be created for shareholders of Perrigo Company plc (NYSE: PRGO; TASE) through Mylans offer to acquire the company. During the call, Mylan will review a comprehensive presentation which outlines the compelling proposition for Perrigo shareholders. Mylans offer represents a very attractive EBITDA multiple, one of the highest ever paid in the industry, and an attractive premium to Perrigos hypothetical unaffected stock price. Mylan also will outline how a combination of the two companies would immediately achieve Perrigos stated business strategy and reduce its future business and performance risk.

Under the terms of Mylans offer, Perrigo shareholders will receive $75 in cash and 2.3 Mylan ordinary shares for each Perrigo ordinary share. On September 14, 2015 Mylan officially commenced its formal offer to acquire all outstanding ordinary shares of Perrigo.

The offer is being made in accordance with Mylans announcement (dated April 24, 2015 and amended on April 29, 2015 and on August 13, 2015) pursuant to Rule 2.5 of Irish Takeover Rules that set forth Mylans legally binding commitment to commence an offer for the entire issued and to be issued share capital of Perrigo. The offer and withdrawal rights are scheduled to expire at 1:00 P.M. (Irish time)/8:00 A.M. (New York City time) on November 13, 2015, unless the offer is extended with the consent of the Irish Takeover Panel. The acceptance condition for the offer requires greater than 50% of Perrigo ordinary shares to have been tendered into the offer.

A copy of the Offer to Exchange/Prospectus (being the offer document for the purposes of the Irish Takeover Rules) and other related materials have been mailed to Perrigo shareholders and the Offer to Exchange/Prospectus is available at

The dial-in number to access the call is 800.514.4861 or 678.809.2405 for international callers. To access the live webcast, please log on to Mylans website,, at least 15 minutes before the event is scheduled to begin to register and download or install any necessary software.

The presentation will be made available at and the other materials related to Mylans offer are also available at .


Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do whats right, not whats easy; and impact the future through passionate global leadership. We offer a growing portfolio of around 1,400 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which nearly 50% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in about 145 countries and territories. Our workforce of approximately 30,000 people is dedicated to creating better health for a better world, one person at a time. Learn more at


This communication contains forward-looking statements. Such forward-looking statements may include, without limitation, statements about the proposed acquisition of Perrigo Company plc (Perrigo) by Mylan N.V. (Mylan) (the Perrigo Proposal), Mylans acquisition (the EPD Transaction) of Mylan Inc. and Abbott Laboratories non-U.S. developed markets specialty and branded generics business (the EPD Business), the benefits and synergies of the Perrigo Proposal or EPD Transaction, future opportunities for Mylan, Perrigo, or the combined company and products, and any other statements regarding Mylans, Perrigos, or the combined companys future operations, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, competition, and other expectations and targets for future periods. These may often be identified by the use of words such as will, may, could, should, would, project, believe, anticipate, expect, plan, estimate, forecast, potential, intend, continue, target and variations of these words or comparable words. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: uncertainties related to the Perrigo Proposal, including as to the timing of the offer and a compulsory acquisition, whether Perrigo will cooperate with Mylan and whether Mylan will be able to consummate the offer and a compulsory acquisition, the possibility that competing offers will be...